COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)		12 Months Ended
	Jan. 11, 2023	Sep. 30, 2023	Sep. 30, 2022
Research and development expenses		$ 35,700,000
Net of discount		11,800,000
Additional expenses		700,000
Finance lease liability, current		1,771,804	$ 1,560,553
Operating lease liability, current		197,431	170,928
Operating Expense [Member]
Cash payment for operating leases		$ 300,000	12,000,000
Weighted average operating lease discount rate		10.20%
Operating lease liability, current		$ 200,000	200,000
Operating lease liability		1,900,000	2,100,000
Operating lease right of use assets		$ 1,700,000	1,900,000
Weighted average operating lease maturity year		7 years 8 months 26 days
Lease expenses		$ 400,000	2,400,000
Lease Agreement [Member]
Weighted average maturity year		5 years 1 month 2 days
Finance lease right of use assets		$ 9,100,000	10,900,000
Finance lease liability		11,700,000	13,300,000
Finance lease liability, current		1,800,000	1,600,000
Depreciation expenses		1,800,000	1,800,000
Interest payment to lease liability		1,100,000	1,200,000
Cash payment to lease liability		$ 2,600,000	2,500,000
Weighted average discount rate		8.44%
Landlord [Member]
Incremental borrowing, derivative variable rate		8.45%
Lease description		The repayment includes a base rent which escalates at 3% each year plus interest that accrues at 13.75% per year
Financing arrangement		$ 11,100,000
Payments Made to Landlord	$ 2,300,000	2,400,000
Ergomed [Member]
Research and development expenses		200,000	$ 500,000
Net of discount		100,000
Clinical service trial		10,000,000
Additional clinical trial		$ 2,000,000